CoChat

The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review

Aroda, Vanita R., Ratner, Robert · 2011 · Diabetes/Metabolism Research and Reviews
Cited by 112

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Although several classes of pharmacotherapy are available for type 2 diabetes, glycaemic control is often hampered by medication‐related adverse effects and contraindications such as renal impairment. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists provide a new pharmacotherapeutic option based on the multiple glucose‐lowering effects of the human hormone GLP‐1. This mechanism of action not only provides therapeutic efficacy but also suggests that GLP‐1 receptor agonists have distinct safety and tolerability concerns compared with other diabetes therapies. Stimulation of pancreatic insulin secretion by GLP‐1 receptor agonists is glucose dependent, conferring a lesser risk of hypoglycaemia than that seen with sulfonylureas. Individual GLP‐1 receptor agonists differ in their metabolism and excretion profiles, affecting the choice of agent for patients with renal impairment. As with other protein‐based therapies, GLP‐1 receptor agonists may induce the formation of antibodies that may attenuate therapeutic efficacy and affect safety. Conclusions on cardiovascular safety must await outcomes studies, but at present no signal of harm has been reported, and preclinical data and effects on risk markers suggest a potential for benefit. Current data on thyroid medullary cancer in humans and pancreatic malignancy in rodents do not suggest that there is any reason to restrict the clinical use of GLP‐1 analogues in most people with diabetes. It is currently difficult to ascertain the possible contributory role of GLP‐1 receptor agonists in increasing the risk of pancreatitis, and vigilance for signs and symptoms is prudent. Primary tolerability issues include transient gastrointestinal symptoms, common with GLP‐1 receptor agonists, which can be reduced through dose titration. Copyright © 2011 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.1202

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 112

Metadata

Authors
Aroda, V. R., & Ratner, R.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2011-09
Volume
27
Issue
6
Pages
528-542
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W2007910256
Cited by
112
References
36
FWCI
10.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.